Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria
Susan A. Charman(Monash University), Jonathan L. Vennerstrom(Nebraska Medical Center), Darren J. Creek(Monash University), Julia Morizzi(Monash University), J. Carl Craft(Medicines for Malaria Venture), K. Sriraghavan(Vellore Institute of Technology University), Sergio Wittlin(Swiss Tropical and Public Health Institute), Michael J. Campbell(University of Sheffield), Jacques Chollet, David M. Shackleford(Monash University), Ian Bathurst(Medicines for Malaria Venture), Yuxiang Dong(University of Nebraska Medical Center), Christian Scheurer(Swiss Tropical and Public Health Institute), Heinrich Urwyler(Basilea Pharmaceutica (Switzerland)), Karen L. White(Monash University), Sarah Arbe‐Barnes(Aptiv (Ireland)), Hugues Matile(Roche (Switzerland)), Lukas Stingelin(Monash University), Petros Papastogiannidis(Swiss Tropical and Public Health Institute), Xiaofang Wang(Chinese Academy of Tropical Agricultural Sciences), Tien Thuy Nguyen(Monash University), Yuanqing Tang(Chengdu Organic Chemicals (China)), Lin Zhou(University of Nebraska Medical Center), Reto Brun(Swiss Tropical and Public Health Institute), Melanie Maurer(Swiss Tropical and Public Health Institute), Francis C. K. Chiu(Monash University), William N. Charman(Monash University)
Cited by 379
Related Papers
Analysis of serial measurements in medical research.
|BMJ|1990|3.2k
CONSORT 2010 statement: extension to randomised pilot and feasibility trials
|Pilot and Feasibility Studies|2016|3k
Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable
|Statistical Methods in Medical Research|2015|2k